AU Patent

AU2013202187A1 — Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders - D1

Assigned to Avanir Pharmaceuticals Inc · Expires 2013-05-02 · 13y expired

What this patent protects

P:\OPER\DAH\Speci\OO8\30526934.doc-18/04/2008 Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

USPTO Abstract

P:\OPER\DAH\Speci\OO8\30526934.doc-18/04/2008 Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

Drugs covered by this patent

dextromethorphan-hydrobromide (DEXTROMETHORPHAN HYDROBROMIDE)

Patent Metadata

Patent number: AU2013202187A1
Jurisdiction: AU
Classification: —
Expires: 2013-05-02
Drug substance claim: No
Drug product claim: No
Assignee: Avanir Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.